Quantum BioPharma Ltd. (QNTM) is an innovative biotechnology company focused on advancing transformative therapies for oncology and autoimmune diseases. With a robust pipeline of biopharmaceutical products, QNTM is committed to utilizing cutting-edge research and development to address critical unmet medical needs in these therapeutic areas. The company's strategic partnerships and experienced leadership position it to successfully navigate the complexities of the biopharmaceutical landscape. As the demand for groundbreaking therapeutics rises, Quantum BioPharma presents a strong investment opportunity for institutional investors seeking exposure to the dynamic healthcare sector.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-14.33M |
| Operating Margin | 0.00% |
| Return on Equity | -2057.00% |
| Return on Assets | -62.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.10 |
| Price-to-Book | 31.98 |
| Price-to-Sales (TTM) | 91.86 |
| EV/Revenue | 98.56 |
| EV/EBITDA | -1.57 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $6.40M |
| Float | $5.96M |
| % Insiders | 12.36% |
| % Institutions | 11.46% |
Volatility is currently contracting
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
AUSTIN, Texas, June 26, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis,” featuring Quantum BioPharma Ltd . (NASDAQ: QNTM) (CSE: QNTM).
NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork ), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork ), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
Disseminated on behalf of Quantum BioPharma , may include paid advertisements. AUSTIN, Texas, June 02, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
TORONTO, June 02, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum” or the “Company”), a biopharmaceutical company focused on advancing innovative therapies and technologies, is pleased to announce that it has entered into an investor relations and consulting services agreement with Stocks.news through IR Agency LLC (the “Agency”) beginning on June 8, 2026.
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum” or the “Company”), a biopharmaceutical company focused on advancing innovative therapies and technologies, today announced a significant milestone in its collaborative study with Massachusetts General Hospital (MGH): patient enrollment has reached the halfway mark, accompanied by encouraging preliminary imaging results.
TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum” or the “Company”), has reported its financial and operational results for the first quarter of 2026, ended March 31, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on QNTM and any ticker you trade — then tracks every position and per-strategy win rate.
